Physicochemical Properties
| Molecular Formula | H3N |
| Molecular Weight | 17.0305197238922 |
| Exact Mass | 341.063 |
| CAS # | 134729-13-8 |
| PubChem CID | 10042938 |
| Appearance | Typically exists as solid at room temperature |
| LogP | 2.9 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 3 |
| Heavy Atom Count | 24 |
| Complexity | 581 |
| Defined Atom Stereocenter Count | 0 |
| InChi Key | NKBRWXWNSUIHNI-UHFFFAOYSA-N |
| InChi Code | InChI=1S/C17H12FN3O2S/c1-24(22,23)16-8-2-12(3-9-16)17-10-14(11-19)20-21(17)15-6-4-13(18)5-7-15/h2-10H,1H3 |
| Chemical Name | 1-(4-fluorophenyl)-5-(4-methylsulfonylphenyl)pyrazole-3-carbonitrile |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets |
Cyclooxygenase-2 (COX-2) (IC₅₀ = 0.24 μM, with no inhibition of COX-1 at 100 μM) [1] |
| ln Vitro |
COX-2-IN-2 does not inhibit COX-1, not even at 100μM [1]. COX-2-IN-2 shows potent inhibitory activity against recombinant human COX-2 enzyme with an IC₅₀ value of 0.24 μM. It exhibits no inhibitory activity against COX-1 even at a concentration of 100 μM. [1] |
| ln Vivo |
For collagen-induced arthritis and adjuvant-induced arthritis, the oral ED50 values of COX-2-IN-2 are 0.47 and 0.030 mg/kg, respectively, and the ED30 value for yeast-induced hyperalgesia is 7.4 mg/kg (Randall-Selitto)). COX-2-IN-2 is non-ulcerogenic and exhibits good analgesic efficacy [1]. In adjuvant-induced arthritis model in rats, oral administration of COX-2-IN-2 at 0.030 mg/kg showed significant anti-inflammatory effect. In collagen-induced arthritis model, the ED₃ value was 0.47 mg/kg orally. In yeast-induced hyperalgesia (Randall-Selitto assay), the ED₃ value was 7.4 mg/kg orally. [1] |
| Enzyme Assay |
The enzyme assay used CHO cells expressing recombinant human COX-1 or COX-2 as enzyme sources. COX activity was measured as prostaglandin E₂ formation using radioimmunoassay. The enzyme (1 μg/150 μL for COX-1 or 3 μg/150 μL for COX-2) was preincubated with the inhibitor in 0.1 M Tris-HCl buffer (pH 7.3) containing 2 μM hematin and 5 mM L-tryptophan at 30°C for 5 minutes, followed by incubation with arachidonic acid (10 μM) at 30°C for 5 minutes. The reaction was stopped with 1 N HCl, and PGE₂ was extracted with ethyl acetate and measured by radioimmunoassay. [1] |
| Animal Protocol |
Adjuvant arthritis and collagen-induced arthritis experiments were conducted according to previously reported procedures. For yeast-induced hyperalgesia (Randall-Selitto assay), a 5% brewer's yeast suspension in 0.5% methyl cellulose was injected into the right hind paw of Sprague Dawley rats. Pain threshold was measured 3 hours post-injection. Drugs were administered orally 2 hours after yeast injection. [1] |
| References | [1]. Tsuji K, et al. Studies on anti-inflammatory agents. IV. Synthesis and pharmacological properties of 1,5-diarylpyrazoles and related derivatives. Chem Pharm Bull (1997), 45(6), 987-995 |
| Additional Infomation |
COX-2-IN-2 was developed as a selective COX-2 inhibitor to reduce gastrointestinal and renal side effects associated with non-selective NSAIDs. It is a 1,5-diarylpyrazole derivative designed to mimic the structure of DuP697 but with improved stability and safety profile. [1] |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 58.7199 mL | 293.5995 mL | 587.1991 mL | |
| 5 mM | 11.7440 mL | 58.7199 mL | 117.4398 mL | |
| 10 mM | 5.8720 mL | 29.3600 mL | 58.7199 mL |